At Travere Therapeutics, we are committed to supporting independent educational activities that increase understanding of how to improve the care of patients with rare disease

Travere may support medical education grant applications for independent education designed to close knowledge gaps identified in the healthcare landscape, drive measurable improvements in knowledge and performance of healthcare professionals, and advance patient health outcomes.

“Independent” means that the projects funded by the companies are the full responsibility of the recipient organization. Travere does not have influence over any aspect of the supported projects and only ask for interim and final outcomes reports including a description of the impact of the projects. The program must be of high quality, unbiased, innovative, and evidence based. Travere may provide medical education grants to support independent programs for healthcare professionals, patients, consumers, and healthcare associations, foundations and institutions, in which the programs relate to our therapies and therapeutic focus.


Educational providers and the activities they develop must be compliant with all applicable legal and regulatory guidelines, and the ethical standards under which Travere conducts business. A medical education grant application must be compliant with the current guidelines including AMA Guidelines on Gifts to Physicians, the AMA Ethical Opinion on Continuing Medical Education, the ACCME Standards for Commercial Support, the US Food and Drug Administration’s December 3, 1997 Final Guidance for Industry Supported Scientific and Educational activities, the OIG Compliance Program Guidance for Pharmaceutical Manufacturers, and the PhRMA Code of Interactions with HealthCare Professionals.

Our medical education grant areas of interest

Education for nephrologists, allied health professionals, and primary care providers on:

  1. Burden of disease, unmet need and benefits of early referral and treatment in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)
  2. The dual roles of endothelin-I and angiotensin II in the pathophysiology of IgAN and FSGS
  3. The treatment landscape in IgAN, including:
    • Treatment guidelines, available treatments, combining treatments
    • Sparsentan, its unique mechanism of action, clinical efficacy and safety data, and place within the treatment paradigm


Travere Therapeutics may support the following types of medical educational grants:

  • Medical educational grants can be certified educational programs (CME/CE)
  • Activities for non-accredited education of healthcare professionals or patients, and strictly for educational purposes


Grants Portal

There are no active RFPs available at this time. Please continue to check back.

Any personal data you provide Travere Therapeutics will be processed according to our Privacy Policies.